BioSig Technologies, Inc. (NASDAQ:BSGM) or ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer.
Save time and jump to the most important pieces.
Los Angeles, CA, Oct. 22, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB:BSGM) ("BioSig" or the "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced its successful appeal to the NASDAQ Panel, and as a result the Company's common stock will resume trading on the NASDAQ Capital Market Exchange at the open of trading on Wednesday, October 23, 2024. The Company was granted an extension until March 7, 2025, a 360-day grace period from the point at which the Market Value of Listed Securities ("MVLS") requirement previously became non-compliant. BioSig's CEO, Anthony Amato stated, "We'd li
Los Angeles, July 31, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB:BSGM) ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization for electrophysiology (EP) procedures, today announced the intent to acquire the assets of Neuro-Kinesis Corporation (NKC), a privately held Los Angeles-based medical technology company developing smart EP tools. A non-binding letter of intent (LOI) has been executed confirming BioSig's preliminary interest in the proposed acquisition of the assets of NKC. The purchase price will be paid through the issuance of shares of BioSig's common stock to the shareholders o
Los Angeles, CA 90025, July 25, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB:BSGM) or ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, is pleased to announce that it has successfully negotiated with multiple vendors an initial reduction in accounts payable of approximately $1.5 million during the second quarter of 2024 since new management has taken leadership. One substantial savings recognized is for the successful termination of the office lease expense for the former headquarters in Westport, Connecticut as of July 15, 2024 which was set to end on December 31, 2024.
4 - BioSig Technologies, Inc. (0001530766) (Issuer)
4 - BioSig Technologies, Inc. (0001530766) (Issuer)
4 - BioSig Technologies, Inc. (0001530766) (Issuer)
PRE 14A - BioSig Technologies, Inc. (0001530766) (Filer)
8-K - BioSig Technologies, Inc. (0001530766) (Filer)
8-K - BioSig Technologies, Inc. (0001530766) (Filer)
SC 13G - BioSig Technologies, Inc. (0001530766) (Subject)
SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)
SC 13G - BioSig Technologies, Inc. (0001530766) (Subject)
The Benchmark Company initiated coverage of BioSig Technologies with a rating of Buy and set a new price target of $42.00
Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 11.1% to $1.3 during Tuesday's after-market session. The company's market cap stands at $24.4 million. Unicycive Therapeutics (NASDAQ:UNCY) stock increased by 6.09% to $0.69. The company's market cap stands at $26.1 million. Venus Concept (NASDAQ:VERO) stock increased by 5.71% to $1.11. The company's market cap stands at $7.0 million. Gossamer Bio (NASDAQ:GOSS) stock moved upwards by 4.99% to $0.54. The market value of their outstanding shares is at $121.2 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved upwards by 4.86% to $5.82. The market value of their outstanding shares is at $185.1 million. Poseida Therapeuti
BioSig Technologies (NASDAQ:BSGM) shares are trading lower by 67% to $0.55 during Tuesday’s session after the company said it was notified by the Nasdaq Hearings Panel that its common stock will be delisted from the Nasdaq Stock Market due to non-compliance with the minimum stockholders’ equity requirement. Consequently, trading of the company’s stock will be suspended on Nasdaq starting June 12. The stock is expected to trade on the OTC Markets’ Pink Current Information tier under the symbol “BSGM” beginning the same day. The company intends to request the Panel’s reconsideration and appeal the decision to the Nasdaq Listing and Hearing Review Council, although there is no assurance
Westport, CT, June 10, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) or ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer. Personal Bio, Ferdinand Groenewald, age 39Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director
Westport, CT, April 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) or ("BioSig" or "the Company"), a medical technology Company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Anthony Amato to the Position of Chief Executive Officer ("CEO"), effective immediately. Additionally, Mr. Amato will serve on the Company's Board of Directors, which is currently being assembled. Recall, that on April 4, 2024, the Company announced the engagement of Consulting firm, Bridge Associates International Pharmaceutical Consulting ("BAIPC"), led by Mr. Amato. This corporate action was the natural progressi
Westport, CT, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Westport, CT, November 7, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, announced the appointment of Frederick Hrkac to the new role of Executive Vice President, effective as of November 2, 2023. Mr. Hrkac has a 32-year career in medical devices, as an executive and corporate director, covering much of the globe. Since April 2022, he has served on the BioSig Board of Directors and as Chairman of the nominating and corporate governance committee. As a result of his appoi
Westport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the release of PURE EP™ Software Version 6 with ACCUVIZ™ Module. Built around three highly differentiating features, PURE EP™ Software Version 6 with ACCUVIZ™ Module introduces the proprietary High Frequency Algorithm (HFA), a novel feature that identifies the key frequency components of cardiac data that can be difficult to identify within the traditional waveform presentation. O
Westport, CT, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a conference call on Tuesday, December 21, 2021, at 2 PM ET. Conference Call DetailsDate: Tuesday, December 21, 2021Time: 2:00 PM Eastern Time (ET)Dial-in number for US callers (toll-free): 877-407-8293Dial-in number for U.S. and international callers (toll): +1 201-689-8349 To join the conference call online, please click here: BioSig Webcast A